Instil Bio (TIL) Earnings Date & Reports

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer... Show more

Industry: #Precious Metals

Get AI intraday signals

A.I. Advisor

published Earnings

TIL is expected to report earnings to fall 81.73% to -189 cents per share on March 04

Q4'23

Est.

$-1.90

Q3'23

Missed

by $4.30

Q2'23

Beat

by $0.01

Q1'23

Missed

by $8.51

Q4'22

Missed

by $6.79

The last earnings report on November 13 showed earnings per share of -1039 cents, missing the estimate of -609 cents. With 36.26K shares outstanding, the current market capitalization sits at 119.49M.

View a ticker or compare two or three

Compare

TIL